Torbjörn Bjerke has served as a member of SynAct Board of Directors since 2016. Dr. Bjerke is currently the portfolio manager of Arctic Aurora LifeScience. He previously served as the President and Chief Executive Officer of Karolinska Development AB from 2011 to 2014. Prior to that, Dr. Bjerke was the President and Chief Executive Officer of Orexo AB, a position he held from 2007 until January 2011. Previously, he was President and Chief Executive Officer of Biolipox AB, Executive Vice President, R&D, ALK Pharmaceuticals, and Director of Pharmacology at AstraZeneca. Dr. Bjerke holds a Ph.D. in Medicine from Aarhus Universitet.
Bjerke is co-founder of Action Pharma AS and TXP Pharma GmbH. Action Pharma sold its lead drug development candidate to AbbVie for 110 MUSD and TXP Pharma sold various rights to Questcor Pharmaceuticals for 100 MUSD in milestone payments. In addition Bjerke has experience from a number of board engagements within Life Science such as DBV Technologies, NeuroSearch AS, TopoTarget AS, Axelar AB, Aprea AB och Pergamum AB.
Bjerke holds 100 procent of the shares in GLCapital AB, which holds shares in SynAct Pharma AB.
Holdings: 763 512
John Haurum, MD
John Haurum is a non-executive Director in European biotech companies AgomAb Therapeutics, Synklino Aps, Synact and Neophore. Previously, he was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. Previously he was VP Research at ImClone Systems, New York (2010-2012) and before then he was the Chief Scientific Officer and cofounder of Symphogen A/S, Denmark (2000-2009).
After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.
Haurum holds shares in SynAct Pharma AB
Terje Kelland, MD
Terje Kalland, MD och Ph.D., has more than 30 years of international experience from management positions in the Life Science industry. He has been Senior Vice President at Novo Nordisk A/S, head of research and development at Biovitrum AB (now SOBI AB) and various positions within Pharmacia AB. Kalland has substantial experience with financing and investment activities and as vice president at Karolinska Development AB. He was professor in tumour immunologi at Lunds Universitety and has experience with boards from several listed companies in Sweden and internationally.
Kalland holds shares in SynAct Pharma AB.
Thomas Jonassen is associate professor at Cardiovascular Pharmacology, University of Copenhagen and visiting professor at William Harvey Research Institute, Barts and London School of Medicine. Jonassen has published more than 50 scientific publications and is inventor of 6 granted patents in USA and Europe.
Jonassen is co-founder and current CSO at SynAct Pharma AB, co-founder of ResoTher Pharma Aps and co-founder and former CSO at Action Pharma A/S and co-founder of TXP Pharma Gmbh. Action Pharma sold its lead drug development candidate to AbbVie for 110 MUSD and TXP Pharma sold various rights to Questcor Pharmaceuticals for 100 MUSD in milestone payments.
Jonassen is co-inventor of SynActs drug candidate AP1189.
Jonassen holds shares in SynAct Pharma AB.
Holdings: 2 236 971
Holdings in SynAct Pharma AB as of December 31, 2019.